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http://dx.doi.org/10.1016/j.ccr.2013.01.022SUMMARYThe epithelial-mesenchymal transition (EMT) enhances cancer invasiveness and confers tumor cells with
cancer stem cell (CSC)-like characteristics. We show that the Snail-G9a-Dnmt1 complex, which is critical
for E-cadherin promoter silencing, is also required for the promoter methylation of fructose-1,6-biphospha-
tase (FBP1) in basal-like breast cancer (BLBC). Loss of FBP1 induces glycolysis and results in increased
glucose uptake, macromolecule biosynthesis, formation of tetrameric PKM2, and maintenance of ATP
production under hypoxia. Loss of FBP1 also inhibits oxygen consumption and reactive oxygen species
production by suppressing mitochondrial complex I activity; this metabolic reprogramming results in an
increased CSC-like property and tumorigenicity by enhancing the interaction of b-catenin with T-cell factor.
Our study indicates that the loss of FBP1 is a critical oncogenic event in EMT and BLBC.INTRODUCTION
The increased motility and invasiveness of metastatic tumor
cells are reminiscent of the events that occur at the epithelial-
mesenchymal transition (EMT), a characteristic of embryonic
development, tissue remodeling, and wound healing (Polyak
and Weinberg, 2009; Thiery et al., 2009). EMT also bestows
tumor cells with cancer stem cell (CSC)-like characteristics,
providing them with therapeutic resistance and conferred tumorSignificance
BLBC is associated with an aggressive clinical history, develop
survival. BLBC contains abundant EMT markers and possesse
associates with these changes remain unknown. We showed
sion in BLBC; this results in increased CSC-like characteristics
suppressing ROS production. This metabolic reprogramming is
FBP1 is required for EMT induction, the conversion from lumina
survival. Our study suggests that targeting the Snail complex
316 Cancer Cell 23, 316–331, March 18, 2013 ª2013 Elsevier Inc.recurrence. Although metabolism plays a fundamental role in
essentially every function of a cell, little is known about how
the cell’s metabolism contributes to the morphological and
molecular changes in EMT. Understanding the causes and
consequences of altered metabolism, particularly glucose, in
EMT may permit the identification of drug targets for treating
metastatic breast cancer.
Glucose homeostasis is reciprocally controlled by the cata-
bolic glycolysis/oxidative phosphorylation (OXPHOS) and thement of recurrence, distant metastasis, and shorter patient
s many CSC-like characteristics, but the metabolic program
that the Snail-G9a-Dnmt1 complex repressed FBP1 expres-
and tumorigenicity by enhancing aerobic glycolysis and by
intertwined with the development of BLBC, because loss of
l to basal-like phenotype, and is associatedwith poor patient
may be an effective approach for treating BLBC.
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Metabolic Reprogramming by Snailanabolic gluconeogenesis pathway. In the catabolic reaction,
glucose is converted to pyruvate in the absence of oxygen,
which can be further metabolized to lactate in the cytoplasm
(glycolysis). In the presence of oxygen, pyruvate is channeled
to the tricarboxylic acid (TCA) cycle to fuel OXPHOS for the
maximal ATP production in the mitochondria. Otto Warburg
noticed that some tumor cells preferentially metabolized glucose
to lactate in the presence of ample oxygen, a process called
aerobic glycolysis (Koppenol et al., 2011). Activation of several
oncogenes contributes to the Warburg effect in tumor cells.
For example, AKT1 stimulates glucose uptake by enhancing
Glu-4 expression and by activating hexokinase (Elstrom et al.,
2004; Robey and Hay, 2009). Activation of Myc also induces
glycolysis by inducing LDH-A and PDK1 expression, which
inhibits the conversion of pyruvate to acetyl-CoA and facilitates
the production of lactate (Dang et al., 2008). Tumor cells can
increase an embryonic form of pyruvate kinase M2 (PKM2) to
trigger glycolysis in lung cancer (Christofk et al., 2008).
Much attention has focused on regulation of the catabolic
pathway of glucose. Gluconeogenesis is less investigated and
may play an equally important role in the switch to aerobic
glycolysis in tumor cells. Fructose-1,6-bisphosphatase (FBP1),
which catalyzes the splitting of fructose-1,6-bisphosphate
(F-1,6-BP) into fructose 6-phosphate and inorganic phosphate,
is a rate-limiting enzyme in gluconeogenesis. An autosomal
recessive inherited disorder of FBP1 deficiency is characterized
by hypoglycemia and lactic acidosis, which often causes sudden
infant death (Emery et al., 1988). This suggests that loss of FBP1
increases glucose uptake and glycolysis, leading to hypogly-
cemia and lactic acidosis in patients. Consistent with these
observations, inhibition of FBP1 significantly increases glucose
sensitivity and utilization in type 2 diabetic mouse models (van
Poelje et al., 2006). Interestingly, loss of FBP1 expression due
to promoter DNA methylation has been observed in liver, colon,
and gastric cancers (Chen et al., 2011; Liu et al., 2010), suggest-
ing that epigenetic regulation of FBP1 plays a critical role in
modulating glucose metabolism in cancer.
Breast cancer can be divided into four subtypes based on
gene expression profiling: luminal A, luminal B, HER2, and
basal-like (BLBC). BLBC is defined by expression of markers
characteristic of basal/myoepithelial cells and is identified as
a subgroup of breast cancers that may originate from undifferen-
tiated stem cells (Polyak, 2011). Consistent with this notion,
BLBC contains many EMT markers and CSC-like characteris-
tics. We recently showed that Snail interacted with H3K9
methyltransferase G9a and DNA methyltransferase Dnmt1 to
silence E-cadherin expression in BLBC cells (Dong et al.,
2012). We carried out this study to identify other targets regu-
lated by the Snail-G9a-Dnmt1 complex and investigate their
contributions to BLBC.
RESULTS
FBP1 Expression Is Inversely Correlated with Snail
in Breast Cancer
To identify potential targets regulated by the Snail-G9a-Dnmt1
complex, we performed microarray analysis in MDA-MB231
cells with knockdown of G9a (GSE34925). Similar to E-cad-
herin, FBP1 mRNA was greatly elevated after knockdown ofG9a. FBP1 has been identified as a marker to distinguish
estrogen receptor (ER)-positive breast cancer from ER-negative
subtype (van ‘t Veer et al., 2002). To reveal the potential func-
tion of FBP1 in breast cancer, we analyzed FBP1 expression
in five gene expression data sets and noticed that FBP1
expression positively correlated with ERa expression (Fig-
ure S1A available online). In two data sets (NKI295 and
GSE1456) with information on breast cancer subtypes, we
found FBP1 expression was high in luminal subtype and signif-
icantly lower in BLBC (Figure 1A). Using immunohistochemistry
staining, we also found that FBP1 expression positively corre-
lated with ERa expression (Figures 1B and S1B). This correla-
tion was further confirmed using immunoblotting. We found
that FBP1 and ERa were highly expressed in luminal subtype
but lowly expressed in triple-negative breast cancer, which
are mostly also BLBC (Figure S1C; six samples from both cases
are shown in Figure 1C). Consistent with the notion that BLBC
express EMT molecules, Snail protein level was high in triple-
negative breast cancer, and its level inversely correlated with
expression of FBP1, ERa, and E-cadherin (Figures 1C and
S1C). Furthermore, we examined the expression of FBP1,
ERa, and Snail in breast cancer cell lines. BLBC cells lose
expression of luminal epithelial molecules (ERa and E-cadherin)
and contain high levels of mesenchymal markers (vimentin,
N-cadherin, and Snail). Similar to E-cadherin and ERa, FBP1
was high in luminal cell lines and absent in BLBC cell lines
(Figure 1D).
FBP1 Is a Direct Target of Snail
To investigate the causal relationship between Snail and FBP1,
we expressed Snail in two luminal breast cancer cell lines.
Expression of Snail downregulated E-cadherin expression,
induced EMT, and converted luminal cells into basal-like pheno-
type (Dhasarathy et al., 2011) (Figures 2A–2D). This phenotypic
conversion is associated with the loss of luminal markers and
gain of basal markers (Figures 2D and S2). Similar to E-cadherin,
Snail almost completely suppressed FBP1 expression in these
cells (Figures 2B–2D). To examine whether FBP1 repression is
required for Snail-mediated EMT and basal-like phenotype
conversion, Snail was co-expressed with exogenous FBP1
(under the control of CMV promoter and thus not repressed by
Snail) in luminal cells (Figure 2A). Ectopic FBP1 expression
blocked the downregulation of E-cadherin, inhibited morpholog-
ical changes indicative of EMT, and suppressed the basal-like
phenotype conversion in these cells (Figures 2B, 2D, and S2),
indicating that FBP1 repression is required for this event.
We noticed that the FBP1 promoter contained nine consensus
Snail-binding E-boxes (CAGGTG) (Figure 2E). We cloned FBP1
promoter (FL1 = 1669 to +331 bp) and generated several dele-
tion mutants of promoter-luciferase constructs based on the
location of these E-boxes. By expressing a full-length FBP1
promoter reporter (FL1) in HEK293, HeLa, and MCF7 cells, we
found Snail significantly repressed FBP1 promoter activity (Fig-
ure 2F). When the E-box at 1273 bp was deleted (FL1 versus
FL2), we did not notice any changes in Snail-mediated FBP1
promoter-luciferase repression (Figure 2G), suggesting that
the E-box at 1273 is not critical for Snail-mediated FBP1
repression. However, two E-boxes upstream of transcriptional
starting site (TSS) (657 and358 bp) as well as six consecutiveCancer Cell 23, 316–331, March 18, 2013 ª2013 Elsevier Inc. 317
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Figure 1. FBP1 Expression Inversely Correlates with Snail in Breast Cancer
(A) Box-plots indicate FBP1 expression in different subtypes of breast cancer.
(B) Statistical analysis of 150 cases of breast tumor samples immunostained using antibodies against FBP1, ER-a, and a control serum.
(C) Expression of FBP1, ER-a, and Snail were analyzed on fresh frozen tumor samples from six cases of luminal and six cases of triple-negative breast cancer.
(D) Expression of FBP1, ER-a, E-cadherin, Snail, and other EMTmarkers was determined bywestern blotting on five luminal and six BLBC cell lines (MDA-MB231,
MDA-MB435, MDA-MB157, and MDA-MB361 are abbreviated to MDA231, MDA435, MDA157, and MDA361 in all figures).
See also Figure S1.
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Metabolic Reprogramming by SnailE-boxes between TSS and ATG sites were important for Snail-
mediated FBP1 repression, as deletion constructs (FL3 and
FL4) that removed these two regions separately became less
sensitive to Snail-mediated repression (Figure 2H). Mutations
on these E-boxes almost completely abolished Snail-mediated
repression on FBP1 promoter luciferase (Figure 2H).
To examine whether Snail binds to FBP1 promoter, we per-
formed chromatin immunoprecipitation (ChIP) by using three318 Cancer Cell 23, 316–331, March 18, 2013 ª2013 Elsevier Inc.sets of primers (Figure 3A). Primer set 2, which covers nucleo-
tides from 369 to 161, worked effectively and thus was
used for the subsequent ChIP experiments. In cells that had
undergone Snail-mediated EMT (Figure 2B), we found that Snail
was associated with the FBP1 promoter (Figure 3B). In addition,
we found endogenous Snail bound to FBP1 promoter in BLBC
cells but not luminal cell lines (Figure 3C). These results indicate
that FBP1 is a direct target of Snail.
Cancer Cell
Metabolic Reprogramming by SnailLoss of FBP1 Expression Is Associated with Elevated
H3K9me2 and DNA Methylation at the FBP1 Promoter
We hypothesized that the Snail-G9a-Dnmts complex also binds
to the FBP1 promoter and is responsible for FBP1 repression in
BLBC. In three luminal cell lines that had undergone Snail-medi-
ated EMT, we found that downregulation of FBP1 was associ-
ated with an increased G9a and H3K9me2 and decreased
H3K9ac at the FBP1 promoter (Figure 3B). We also found
FBP1 promoter was completely unmethylated in vector control
cell lines; however, de novo DNA methylation occurred at the
FBP1 promoter in cells that had undergone Snail-mediated
EMT (Figure 3B). The increased G9a association, H3K9me2,
and DNA methylation on FBP1 promoter correlated well with
the downregulation of FBP1 in these luminal cell lines (Figure 3B).
We also detected a dramatic increase of H3K9me2 and
decrease of H3K9ac on the FBP1 promoter in six BLBC cell lines
compared to those in five luminal cell lines (Figure 3C). The
increase of H3K9me2 at the FBP1 promoter was likely due to
the association of the Snail-G9a-Dnmts complex because the
occupancy of Snail and G9a at the FBP1 promoter was also
significantly higher in BLBC cell lines than in luminal cell
lines (Figure 3C). Consistently, all BLBC cell lines showed
a significant increase of DNAmethylation on the FBP1 promoter,
whereas no detectable FBP1 promoter DNA methylation in
luminal cell lines was observed (Figure 3C). When analyzing 25
cases of luminal and 16 cases of triple-negative breast tumor
tissues (Figure S1C), we found that the association of G9a and
the level of H3K9me2 and DNA methylation on the FBP1
promoter were significantly increased in triple-negative breast
cancer compared with the luminal subtype (Figure 3D). Knock-
down of G9a in MDA-MB231 cells increased the mRNA and
protein levels of FBP1 in a way similar to that of E-cadherin
(Figure 3E). Knockdown of Snail also increased the expression
of FBP1 and E-cadherin in MDA-MB231 cells (Figure S3).
Together, these results indicate that the association of Snail
and G9a and the corresponding increased H3K9me2 and DNA
methylation on FBP1 promoter are critical for the silencing of
FBP1 expression in BLBC.
FBP1 Inhibits Glucose Uptake and Sensitivity
in BLBC Cells
To examine the function of FBP1 in breast cancer, we estab-
lished stable clones with FBP1 expression or knockdown in six
BLBC and two luminal breast cancer cell lines, respectively (Fig-
ure 4A). We first measured glucose uptake and found that FBP1
expression significantly decreased glucose uptake in BLBC cell
lines, whereas knockdown of FBP1 enhanced glucose uptake in
luminal cell lines (Figure 4B). Intracellular glucose is sensed by
MondoA and ChREBP (Li et al., 2006). Following an increase in
intracellular glucose-derived metabolites, MondoA and ChREBP
shuttle to the nucleus, where they interact with Mlx and activate
transcription of target genes. TXNIP is a major direct target of
MondoA-Mlx complex and is commonly used as an intracellular
glucose sensor (Peterson et al., 2010). We thus examined TXNIP
induction by depleting glucose for 12 hr, followed by glucose
stimulation for additional 3 hr. TXNIP was robustly induced in
BLBC cell lines; however, FBP1 suppressed TXNIP induction.
In contrast, knockdown of FBP1 stimulated TXNIP induction in
luminal cells (Figure 4C). Because the cells had been glucose-deprived for 12 hr, the TXNIP levels were re-set to baseline
(lane 2 versus lane 1, Figure S4A); the induction of TXNIP after
glucose stimulation reflects glucose uptake and resultant
steady-state level of intracellular glucose. Indeed, following
glucose stimulation for different time intervals, TXNIP induction
was greatly delayed in FBP1-expressing MDA-MB231 cells. In
contrast, TXNIP induction was robustly increased in FBP1-
knockdown MCF7 cells (Figure S4A). Because insulin is the
major hormone regulating glucose uptake, we measured insulin
sensitivity by examining tyrosine phosphorylation of the insulin
receptor (IR) after insulin stimulation. We found that FBP1
expression suppressed the intensity and duration of IR phos-
phorylation in BLBC cell lines. Conversely, knockdown of FBP1
increased the intensity and duration of IR phosphorylation in
luminal cell lines (Figure S4B). These results indicate that FBP1
is critical in inhibiting glucose uptake exemplified by downregu-
lating glucose and insulin sensitivities.
FBP1 Reduces Lactate Generation and Increases
Oxygen Consumption in BLBC Cells
To examine whether FBP1 changes glucose metabolism from
aerobic glycolysis to OXPHOS, we measured lactate production
and found that FBP1-expressing BLBC cells produced less
lactate than their vector control cells, whereas FBP1-knockdown
luminal cells had more lactate production (Figure 4D). We then
investigated FBP1’s role on cell growth under different oxygen
conditions. At normoxic condition (21% oxygen), FBP1 expres-
sion induced a minor inhibition in cell growth in BLBC cell lines.
Similarly, knockdown of FBP1 did not cause an apparent effect
on the growth of luminal cells (Figure S4C). However, under
hypoxic condition (0.1% oxygen), FBP1 expression induced
a drastic growth inhibition in BLBC cell lines, whereas knock-
down of FBP1 significantly reduced hypoxia-mediated growth
inhibition in luminal cell lines (Figure 4E), suggesting that the
effect of FBP1 on cell growth depends on oxygen. We thus
examined oxygen consumption rate (OCR). We found that the
basal OCR significantly increased in FBP1-expressing BLBC
cells, whereas FBP1-knockdown luminal cells displayed
a decrease in basal OCR (Figure 4F). Similar results were ob-
tained in the analysis of ATP-linked and maximal OCR
(Figure 4F).
FBP1 Inhibits Glycolysis and Increases OXPHOS
For every glucose molecule a cell consumes, aerobic glycolysis
produces 2 ATP, whereas OXPHOS produces 36 ATP. We
found that FBP1 expression or knockdown did not alter the
steady-state level of ATP in BLBC or luminal cells under nor-
moxic condition (Figure S5A). However, under hypoxia, the
steady-state level of ATP was significantly decreased in
FBP1-expressing BLBC cells, whereas knockdown of FBP1
greatly reduced hypoxia-mediated ATP reduction in luminal
cells (Figure S5A). Consistent with these observations, oligomy-
cin treatment resulted in a significant growth inhibition in FBP1-
expressing BLBC cells. Conversely, knockdown of FBP1
provided luminal cells with resistance to this compound (Fig-
ure S5B). Although BLBC cell lines are less sensitive to growth
inhibition mediated by hypoxia or oligomycin compared with
their FBP1-expressing clones, they were extremely sensitive to
glucose deprivation, as indicated by massive cell death andCancer Cell 23, 316–331, March 18, 2013 ª2013 Elsevier Inc. 319
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Figure 2. Snail Represses FBP1 Expression
(A) Schematic diagram showing that Snail was coexpressed with vector (GFP) or FBP1 (CMV promoter) in luminal subtype breast tumor cells.
(B) Snail was coexpressed with vector (GFP) or FBP1 inMCF7 and T47D cells for 4 days. Morphologic changes indicative of EMT are shown in the phase contrast
images; expression of FBP1 and E-cadherin were analyzed by immunofluorescent staining. Nuclei were visualized with DAPI (blue). Scale bar = 20 mm.
(C) The mRNA levels of E-cadherin and FBP1 were quantitated by real-time PCR (mean ± SD in three separate experiments).
(D) Expression of E-cadherin, FBP1, Snail, luminal markers (ER-a and FoxA1), and basal markers (EGFR, SPARC, and Caveolin-1) for cells in (B) was analyzed by
western blotting.
(E) Schematic diagram showing positions of nine potential Snail-binding E-boxes on the FBP1 promoter and FBP1 promoter luciferase construct used.
(legend continued on next page)
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Metabolic Reprogramming by Snaildetachment from the cell substratum after 48 hr of glucose
depletion (Figure S5C).
We further investigated the metabolic fate of [U-13C]-glucose
in vector- and FBP1-expressing MDA-MB231 cells by using
stable isotope-resolved metabolomics (SIRM) (Fan et al.,
2009; Fan et al., 2011; Le et al., 2012). Nuclear magnetic reso-
nance (NMR) analysis of the culture media demonstrated
a reduced 13C6-glucose uptake and
13C3-lactate excretion,
leading to an overall decrease of 13C6-glucose to
13C3-lactate
conversion in FBP1-expressing cells (Figures 5A and S5D).
NMR analysis of 13C-labeled metabolites in cell extracts also
indicated a reduced 13C3-lactate in FBP1-expressing cells (Fig-
ure 5B), consisting of reduced 13C3-lactate excretion into the
media. Interestingly, FBP1 expression also reduced 13C abun-
dance in the ribosyl unit of ribonucleotides and derivatives
(i.e., AXP, UXP, NAD+, and UDPG) (Figure 5B), suggesting
that the pentose phosphate pathway (PPP), which is respon-
sible for generating ribose-5-phosphate for the synthesis of
ribonucleotides and NADPH production, is inhibited. In line
with this finding, the ratio of NADP+/NADPH was increased in
FBP1-expressing MDA-MB231 cells, whereas this ratio was
decreased in FBP1-knockdown MCF7 cells (Figure S5E). The
decreased level of 13C-UDPG in FBP1-expressing cells
suggests that the glycosylation process is reduced. The same
cell extracts were further analyzed by GC-MS to quantify
13C-metabolites involved in glycolysis and the TCA cycle
(Figure 5C). We found that the production of the m3 or 13C3-iso-
topologues of glycerol-3-phosphate (G3P) and serine were
significantly reduced in FBP1-expresing cells, which is
again consistent with attenuated glycolytic activity. In line
with the observations that FBP1 increased OXPHOS, the
production of 13C2 or m2-succinate, fumarate, and malate
(markers of the first turn of the TCA cycle) as well as the
13C4- or m4-citrate (markers of the second turn of the TCA
cycle) (Fan et al., 2010) were increased in FBP1-expressing
cells (Figure 5C). Together, these results indicate that FBP1
inhibits glycolytic flux, reduces biosynthesis (nucleotides via
PPP, G3P for triacylglycerol synthesis, and serine for protein),
and enhances OXPHOS.
FBP1 Suppresses PKM2 Activation and Increases
Mitochondrial Complex I Activity and Reactive Oxygen
Species Generation
To explore the underlyingmechanisms of increased OXPHOS by
FBP1, we first assessed the level of F-1,6-BP. FBP1 expression
caused a dramatic decrease of F-1,6-BP level in BLBC
cells, whereas knockdown of FBP1 led to a marked increase of
F-1,6-BP in luminal cell lines (Figure 6A). We also measured
pyruvate kinase (PK) activity and found that FBP1 significantly
decreased PK activity in two BLBC cell lines; whereas knock-
down of FBP1 increased PK activity in two luminal cells (Fig-
ure S6A). The PK activity contained both PKM1 and PKM2(F) FBP1 promoter luciferase construct (FL1) was coexpressedwith Snail or vector
were determined and normalized (mean ± SD in three separate experiments).
(G) FBP1 promoter luciferase constructs (FL1 and FL2) were coexpressed with S
(H) FBP1 promoter luciferase constructs (FL2, FL3, and FL4 as well as their E-bo
activities were determined as in (F).
See also Figure S2.activities and thus we could not distinguish the activation of
PKM2 by F-1,6-BP. We next examined the tetrameric form of
PKM2 using cross-linking agent. Surprisingly, PKM2 existed
mainly in tetrameric form in two BLBC cell lines, whereas it
appeared in monomer state in two luminal cell lines (Figure 6B).
FBP1 expression significantly decreased the tetrameric PKM2,
whereas knockdown of FBP1 increased the formation of tetra-
meric PKM2. These data indicate that loss of FBP1 activates
PKM2, which facilitates lactate production and triggers the
switch to aerobic glycolysis.
Because FBP1 expression enhanced oxygen consumption,
we reasoned that FBP1 expression stimulates activity in the
mitochondrial electron transport complexes (I, II, III, and IV of
ETC) (Figure 6C). Complexes I and II use electrons donated
from NADH and FADH2, respectively, to reduce coenzyme Q,
which shuttles these electrons to complex III, where they are
transferred to cytochrome c. Complex IV uses electrons from
cytochrome c to reduce molecular oxygen to water. These
actions produce a proton electrochemical potential gradient,
and the free energy released is converted to ATP by ATP syn-
thase (Chatterjee et al., 2011). We first compared the activity of
themitochondrial complexes I and II in terms of their contribution
to the overall oxygen consumption. Complex I and II activity
could be blocked by rotenone and TTFA, respectively, thus the
oxygen consumption relies on the electron transport activity of
the remaining active complex. As shown in Figure 6C, although
OCR was higher in FBP1-expressing BLBC cell lines, addition
of TTFA slightly and proportionally decreased OCR in both
vector- and FBP1-expressing BLBC cells. A consistent trend
was observed in vector- and FBP1-knockdown luminal cell lines
(Figure 6C). However, treatment with rotenone dramatically
reduced OCR in FBP1-expressing BLBC cells to levels found
in vector control cells (Figure 6C). Consistently, treatment with
rotenone also decreased OCR in luminal cells to levels similar
to those found in the FBP1-knockdown luminal cells. We also
measured complex I activity using purified mitochondria from
these cells. FBP1-expressing BLBC cell lines had significant
higher complex I activity, whereas FBP1-knockdown luminal
cell lines had decreased complex I activity (Figure 6D). To
identify the underlying mechanism, we performed microarray
analysis (GSE41158) and determined that mitochondrial tran-
scription factor B1M (TFB1M) was significantly higher in FBP1-
expressing BLBC cells (Figure S6B). TFB1M is a nuclear gene
encoding mitochondrial transcription factor that is essential for
the mitochondrial biogenesis (Metodiev et al., 2009). Loss of
TFB1M causes defects of protein translation in mitochondrial
complex I components, resulting in impaired OXPHOS (Koeck
et al., 2011). We found that TFB1M expression was increased
in FBP1-expressing MDA-MB231 cells, whereas its expression
was decreased in FBP1-knockdown MCF7 cells (Figures S6B
and S6C). In addition, two targets of TFB1M from mitochondrial
complex I, ND1 and ND5, but not components from complexin HEK293, HeLa, andMCF7 cells, respectively. After 48 hr, luciferase activities
nail or vector in HEK293 cells. Luciferase activities were determined as in (F).
x mutants) were coexpressed with Snail or vector in HEK293 cells. Luciferase
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Figure 3. Snail and G9a Are Required for H3K9me2 and DNA Methylation at the FBP1 Promoter
(A) Three sets of primers used for FBP1 promoter ChIP are shown.
(B andC) The association of Snail andG9a, and the level of H3K9me2 andH3K9ac at the FBP1 promoter in cells that have undergone Snail-mediated EMT (B) and
cell lines from Figure 1D (C) were analyzed by ChIP. DNA methylation at the FBP1 promoter was analyzed by MSP.
(D) The association of G9a, and the level of H3K9me2 and DNA methylation at the FBP1 promoter in luminal (25 cases) and triple-negative (16 cases) breast
cancer tissues were analyzed by ChIP and MSP, respectively. Horizontal lines represent mean values. Statistical analyses (mean ± SD in three separate
experiments) are shown below.
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Metabolic Reprogramming by SnailII-IV were also elevated in FBP1-expressing cells. Together,
these data indicate that the rise of complex I activity is the
main factor underlying the increase of mitochondrial oxygen
consumption in FBP1-expressing cells.
In ETC, a small percentage of electrons are prematurely
leaked to oxygen, mainly from complex I and/or complex III,
forming themajority of reactive oxygen species (ROS; Chatterjee
et al., 2011). To test whether an increase in mitochondrial OCR
and complex I activity by FBP1 would accompany an increase
of ROS, we examined intracellular ROS levels using CellROX
deep red. FBP1-expressing BLBC cells showed a substantial
increase in ROS levels, whereas FBP1-knockdown luminal cell
lines induced a significant decrease of ROS (Figures 6E and
6F). A similar finding was observed for superoxide production
using Mito-Sox Red and DHE staining (Figure S6D). These
data indicate that FBP1 expression contributes to the increase
of cellular ROS.
FBP1 Suppresses CSCs and Inhibits Tumorigenicity
of Breast Cancer
To examine whether FBP1 expression alters CSC characteristics
of BLBC, we examined tumorsphere formation of these cells
under normoxic and hypoxic conditions. FBP1 expression
greatly suppressed tumorsphere formation in BLBC cell lines
(Figure 7A), and this inhibitory effect was enhanced by hypoxia
(Figure S7A). Conversely, knockdown of FBP1 in luminal cell
lines enhanced tumorsphere formation in normoxic condition,
and this effect was also substantiated under hypoxia.
Breast CSCs are enriched in cells with a CD44high/CD24low/
EpCAM+ phenotype (Blick et al., 2010). We found that FBP1
expression significantly reduced the percentage of CD44high/
CD24low/EpCAM+ population in BLBC cell lines (Figures 7B
and 7C). Conversely, knockdown of FBP1 induced a significant
increase of CD44high/CD24low/EpCAM+ population in luminal cell
lines. Because CD44 is a known target of b-catenin, and
because activation of b-catenin is often found in BLBC (DiMeo
et al., 2009; Zeilstra et al., 2008), we reasoned that the elevated
ROS caused by FBP1 expression compromises b-catenin
activity. In the cellular aging process, ROS antagonizes b-cate-
nin activity by shifting the interaction of b-catenin with TCF4
toward FOXO3a (Figure 7D) (Bowerman, 2005; Essers et al.,
2005; Manolagas and Almeida, 2007). We found that b-catenin
interacted with TCF4 in BLBC cells. However, the interaction
of b-catenin with TCF4 was significantly decreased and
substituted with an increased interaction of b-catenin with
FOXO3a in FBP1-expressing cells (Figure 7E). Similarly, knock-
down of FBP1 in luminal cells increased the interaction of b-cat-
enin with TCF4. The differential interactions of b-catenin with
TCF4 were consistent with the luciferase reporter assays
showing that FBP1-expressing cells had lower TOP-Flash and
higher FOXO3a luciferase activities than vector control cells
(Figure S7B). In addition, expression of several target genes of
b-catenin (Axin2, CD44, and ID2) and FOXO3a (CDKN2A and
SOD2) were in line with these binding and promoter luciferase(E) Expression of FBP1 and E-cadherin was examined in MDA-MB231 cells w
quantified by real-time PCR (bottom panel). Data are presented as a percentage o
duplicates).
See also Figure S3.assays (Figure S7C). Consistently, NAC treatment restored the
interaction of b-catenin with TCF4 as well as their luciferase
activities and target gene expression (Figures 7E, S7B, and
S7C). In addition, treatment with NAC and EUK134 restored
tumorsphere formation in FBP1-expressing BLBC cells
(Figure S7D).
We also measured the in vitro tumorigenicity of these cells
using soft-agar assay. Although BT549 and SUM1315 cells
could not form colonies, the other FBP1-expressing BLBC cell
lines had significantly fewer colonies than their corresponding
vector controls; whereas knockdown of FBP1 increased colony
formation in luminal cell lines (Figure 8A). NAC treatment
restored colony growth in FBP1-expressing BLBC cells, indi-
cating that the elevated ROS impairs their tumorigenicity
in vitro (Figure S8A). To examine the tumorigenicity in vivo, we in-
jected mammary fat pads of SCID mice with the following three
pairs of cell lines: (1) vector- and FBP1-expressing MDA-MB231
cells, (2) vector- and FBP1-expressing MDA-MB435 cells, and
(3) vector- and FBP1-knockdown MCF7 cells. As shown in Fig-
ure 8B, FBP1-expressing MDA-MB231 cells failed to form
tumors in all six mice. Similarly, tumors derived from FBP1-
expressing MDA-MB435 cells had a significantly reduced tumor
size compared with vector control cells. In line with these
findings, FBP1-knockdown MCF7 cells showed significantly
enhanced tumor growth compared with vector control cells (Fig-
ure 8B). Strikingly, NAC treatment greatly increased tumor
formation in FBP1-expressing MDA-MB231 and MDA-MB435
cells (Figures S8B and S8C). Together, these data indicate that
FBP1 expression increases ROS production, which compro-
mises CSC properties by shifting the interaction of b-catenin
from TCF4 to FOXO3a, and thus inhibits tumorigenicity in vitro
and tumor formation in vivo.
We then examined the correlation of FBP1 expression with
patient survival in NKI295 that consists of 295 patients with
node-negative breast cancer (van de Vijver et al., 2002). Expres-
sion of FBP1 can separate patients into two prognostic groups,
with high FBP1 expression having a better survival rate (Fig-
ure 8C). This clinical validation supports the finding that FBP1
repression is critical in EMT and BLBC.
DISCUSSION
Our study provides several insights into EMT and breast cancer.
First, loss of FBP1 is essential to trigger glycolytic reprogram-
ming and results in several metabolic benefits in BLBC: (1)
increase glucose uptake and sensitivity as evidenced by
elevated TXNIP and IR phosphorylation after stimulation, (2)
increased glycolytic intermediates for biosynthesis (such as
PPP, glycerol-3-phosphate, and serine), (3) maintenance of
ATP production under hypoxia, and (4) reduced oxygen depen-
dence and ROS production (Figure 8D). These observations
are consistent with the notion that FBP1 deficiency causes hypo-
glycemia and acidosis in patients and that inhibition of FBP1
restores glucose uptake in the type 2 diabetic model.ith knockdown of G9a expression (top panel). Their mRNA levels were also
f non-target control (NTC) values (mean ± SD in three separate experiments in
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(A) Stable clones with FBP1 expression or knockdown were established in six BLBC and two luminal cell lines, respectively.
(B) Glucose uptake was measured.
(C) Cells were deprived for glucose for 12 hr followed by glucose stimulation for additional 3 hr. TXNIP expression was examined by western blotting.
(D) Lactate excretion was measured.
(E) Cell growth under hypoxic condition wasmeasured by cell-count assay for 2 days. Data are presented as a percentage of vector control values for BLBC cells,
whereas data are presented as a percentage of FBP1-knockdown groups for luminal cells (mean ± SD in three separate experiments in triplicates).
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Figure 5. FBP1 Inhibits Glycolysis and Increases OXPHOS
(A) 13C6-Glucose uptake,
13C3-lactate production, and the conversion of
13C6-Glucose to
13C3-lactate were measured by 1D
1H NMR analysis of the media of
vector- and FBP1-expressing MDA-MB231 cells grown in 13C6-Glucose (mean ± SEM in duplicate).
1H NMR spectra from the media are shown in Figure S5D.
(B) A pair of representative 1D 1H{13C} HSQCNMR spectra show the changes in 13C abundance (represented by the intensity of 13C-attached 1H peaks) of various
assigned metabolites elicited by FBP1 expression in MDA-MB231 cells (black, control vector; red, FBP1, bottom panel). The relative 13C abundance of indicated
metabolites from cell extracts was quantified from their HSQC peak intensity (Fan and Lane, 2008) (mean ± SEM in duplicate). Lac, lactate; AXP, adenine
nucleotides; UXP, uracil nucleotides; UDPG, UDP-glucose.
(C) Top left panel shows the expected 13C (C) labeling patterns of glycolytic and TCA cyclemetabolites with 13C6-Glc as tracer. The doubly
13C labeled TCA cycle
metabolites are derived from the first turn of the TCA cycle while the quadruply 13C labeled citrate is produced from the second turn of the cycle. The levels of
several indicated 13C isotopologues of glycolytic and TCA cycle metabolites were obtained from the GC-MS analysis of the same cell extracts as in (B) (mean ±
SEM in duplicate).
See also Figure S5.
Cancer Cell
Metabolic Reprogramming by SnailThe activity of PKM2 oscillates between the activated tetra-
meric form and inactivated monomeric state, which constitutes
the metabolic budget system in tumor metabolism (Mazurek
et al., 2005). F-1,6-BP increases the formation of tetrameric
PKM2. Glucose is then fueled to lactate along with ATP produc-
tion until F-1,6-BP levels drop below a minimum signal level,
which causes the disassembly of the tetrameric PKM2 into
a monomeric state. We found that PKM2 mainly existed in tetra-
meric form in BLBC cells and existed predominantly in a mono-
meric state in luminal cells. This observation corresponds with
the findings that BLBC cells contain a high level of F-1,6-BP,
an increased PK activity, and increased lactate production.
FBP1 expression significantly decreased the formation of tetra-
meric PKM2 in BLBC cells by reducing F-1,6-BP. Because the
major function of glycolysis is to provide high levels of glycolytic
intermediates for biomass synthesis, we speculate that two
modes of PKM2 are used in glycolysis. The first mode is the(F) Oxygen consumption was measured (mean ± SD in three separate experime
For B and D, data are presented as a percentage of vector control values (mean ±
#p < 0.01 for vector control cells compared with their FBP1-expressing or FBP1
See also Figure S4.inhibition of PKM2 (economic mode), which blocks glycolytic
flux for accumulation of intermediates required for biosynthesis.
The second mode is the overall increase of glycolytic flux with
activation of PKM2 (luxury mode). The rise of intermediates
results not from a block of PKM2, but from an increased load
of glycolysis through glucose (Figure 8D). As pointed out by Van-
der Heiden and colleagues, although this seems wasteful, it
ensures that the glycolytic intermediates will not be depleted
and maintain precursor concentrations at constant and ample
levels for allowing maximum biosynthesis during rapid cell
growth (Lunt and Vander Heiden, 2011). Our study indicates
that BLBC cells employ the luxury mode of glycolysis by sup-
pressing FBP1 for increasing glucose assimilation and rapid
channeling of glycolytic intermediates in biosynthesis at the
cost of host.
PKM2 is the main enzyme for ATP production in glycolysis.
This inefficient but faster mode of ATP production may bents in triplicate).
SD in three separate experiments in triplicates). For B, D, and E, *p < 0.01 and
-knockdown clones, respectively.
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Figure 6. FBP1 Suppresses PKM2 Activation and Increases Complex I Activity and ROS Production
(A) F-1,6-BP was measured in FBP1-expressing and FBP1-knockdown clones.
(B) Cells were either treated with (+) or without () 1% formaldehyde (crosslinker; CL) for 20 min immediately after cell lysis. The states of monomer, dimer, and
tetramer of PKM2 were analyzed by western blotting.
(C) Schematic diagram showing the electron transfer from mitochondrial complex I to IV. Cells were treated with Rotenone and TTFA, respectively. Oxygen
consumption was measured (mean ± SD in three separate experiments in triplicate).
(D) Complex I activity was measured from mitochondria isolated from cells in (C).
(legend continued on next page)
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Metabolic Reprogramming by Snailpreferred to meet the cellular demands of BLBC, particularly
under hypoxic condition. Under hypoxia, the steady-state level
of ATP in BLBC cells declined slightly; however, FBP1 expres-
sion resulted in a dramatic plunge in ATP level. This is in line
with the observation that BLBC cells are less sensitive to growth
inhibition under hypoxia or by oligomycin. Given that BLBC cells
are highly invasive, this metabolic switch empowers them to
absorb glucose and maintain ATP level in a nutrient-poor and
hypoxic condition. In addition, the acidic microenvironment
created by excreted lactate facilitates the degradation of extra-
cellular matrix and protects BLBC cells from inhibition by an
immune response at the metastatic site (Figure 8D).
The phenomenon during which increased glucose uptake and
exacerbated glycolytic activity often accompany OXPHOS inhi-
bition is known as a Crabtree effect and had been identified in
tumors and other mitotically active tissues (Crabtree, 1929).
We found that the inhibition of complex I activity is mainly
responsible for the Crabtree effect in BLBC cells. Expression
of FBP1 significantly increased mitochondrial complex I activity
by inducing the expression of TFB1M, which is required for the
translation of ND1 and ND5 of mitochondrial complex I (Koeck
et al., 2011). These data provide mechanistic insights and
support our finding that loss of FBP1 suppresses OXPHOS in
BLBC cells.
Second, our results indicate that the glycolytic switch
enhances CSC characteristics in BLBC by reducing ROS. It
has been noted that somatic cells primarily utilize OXPHOS for
their energy production, whereas pluripotent cells rely on glycol-
ysis (Facucho-Oliveira and St John, 2009). Using an iPSC as
a model in stem cell reprogramming, mitochondria were found
to change from a mature cristae-rich morphology in somatic
cells to more immature spherical and cristae-poor structures in
iPSCs. Intriguingly, the glycolytic change occurs in cells prior
to their acquisition of pluripotent markers, suggesting that the
glycolytic switch plays a causative role in the iPSC reprogram-
ming rather than simply being a consequence of acquiring
pluripotency. The induction of pluripotency with a glycolytic
switch is consistent with the observation that a hypoxic envi-
ronment maintains the stem cell state and hypoxia facilitates
the reprogramming process (Mohyeldin et al., 2010). In the
stem cell niche, protection from ROS is critical for the mainte-
nance of self-renewal of hematopoietic stem cells and human
andmouse breast CSCs (Diehn et al., 2009). These observations
indicate that the self-renewal potential of CSCs is exquisitely
sensitive to the level of ROS. We found that FBP1-expressing
BLBC cells increased OXPHOS and ROS production. The
increased ROS was associated with the suppression of tumor-
sphere and decreased CSC markers (CD44high/CD24low/
EpCAM+). In addition, FBP1 expression in BLBC cells inhibited
tumorigenicity in vitro and suppressed tumor formation in vivo.
Mechanistically, elevated ROS shifts the interaction of b-catenin
from TCF4 to FOXO3a and thus compromises b-catenin
activity, which is essential for the maintenance of pluripotency.(E and F) ROS generation was analyzed by flow cytometry (mean ± SD in three
+p < 0.05 and zp < 0.05 for vector control cells compared with their FBP1-expre
For A and D, data are presented as a percentage of vector control values (mean
vector control cells compared with their FBP1-expressing or FBP1-knockdown c
See also Figure S6.NAC treatment returns the interaction of b-catenin with TCF4
and restores tumorigenicity in vitro and in vivo. Together, these
data indicate that the loss of FBP1 greatly increases CSC traits
by repressing ROS production and maintaining the interaction
of b-catenin with TCF4 in BLBC.
Third, our study indicates that FBP1 is a major downstream
target of Snail in controlling glycolysis. We identified that the
Snail-G9a-Dnmt1 complex, which is required for E-cadherin
silencing, is responsible for FBP1 repression in BLBC. FBP1
silencing is required for Snail-mediated EMT and the conversion
from luminal to basal-like phenotype in breast cancer. In
addition, knockdown of Snail or G9a restores the expression of
E-cadherin and FBP1. Our results indicate that this metabolic
reprogramming (resulting from the loss of FBP1) synergizes
with the loss of E-cadherin to sustain CSC-like properties during
dissemination and metastasis. Our study strengthens the notion
that metabolic reprogramming is inextricably intertwined with
tumorigenesis and fortifies Warburg’s historical claim that
metabolism is an actionable event instead of an accompanied
biomarker in oncogenesis (Ward and Thompson, 2012). Our
study also reveals that the Snail-mediated epigenetic regulation
may represent the Achilles’ heel of BLBC. Thus, targeting this
chromatin modification complex will generate an entirely effec-
tive approach for treating metastatic breast cancer.
EXPERIMENTAL PROCEDURES
Plasmids, siRNA, and Antibodies
FBP1 shRNA was purchased from MISSION shRNA at Sigma-Aldrich (St
Louis, MO). Human FBP1 was amplified from a HeLa cDNA library and
subcloned into pLenti6.3. Antibody information is provided in the Supple-
mental Experimental Procedures.
Cell Culture
Breast cancer cell lines were cultured as described previously (Dong et al.,
2012). For establishing stable transfectants with expression or knockdown
of FBP1, BLBC cells and luminal cells were transfected with pLenti6.3/FBP1
and FBP1 shRNA, respectively; stable clones were selected with puromycin
(300 ng/ml) for 4 weeks.
Immunostaining, Immunoprecipitation, Immunoblotting,
Immunohistochemical Staining
All protocols are described in detail in the Supplemental Experimental
Procedures.
Human Breast Tumors
The frozen fresh tumor samples were collected from resected breast tumors
from patients at the University of Texas MD Anderson Cancer Center with
informed consent and institutional IRB approval. These frozen samples
were snap-frozen in liquid nitrogen and stored at 80C. Data regarding the
stage, grade, and expression of ER-a, PR, and HER2 are described previously
(Dong et al., 2012).
Metabolic Assays
Glucose uptake, lactate production, ATP levels, and PK activity were
measured by assay kits from BioVision (San Francisco, CA). Oxygen
consumption was determined using the Seahorse Extracellular Flux (XF-96)separate experiments in duplicates). Representative images are shown (F).
ssing or FBP1-knockdown clones, respectively.
± SD in three separate experiments in triplicates). *p < 0.01 and #p < 0.01 for
lones, respectively.
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Figure 7. FBP1 Inhibits Tumorsphere Formation and Reduces CSC Population
(A) Tumorsphere formation was assessed under normoxic conditions.
(BandC)TheCSCpopulation (CD44high/CD24low/EpCAM+)wasanalyzedbyflowcytometry.Representative images forMDA-MB231andMCF7cells areshown in (C).
(D) Schematic diagram of the interaction of b-catenin with TCF4 and FOXO3a.
(E) FBP1-expressing BLBC cells (F) as well as in FBP1-knockdown luminal cells (S) were treated with or without NAC overnight; the interactions of b-catenin with
TCF4 and FOXO3a were examined by immunoprecipitating b-catenin following immunoblot of TCF4 and FOXO3a.
For A and B, data are presented as a percentage of vector control values (mean ± SD in three separate experiments in duplicates). *p < 0.01 and #p < 0.01 for
vector control cells compared with their FBP1-expressing or FBP1-knockdown clones, respectively.
See also Figure S7.
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Figure 8. FBP1 Suppresses Tumorigenicity In Vitro and In Vivo
(A) Data of soft-agar assay are presented as a percentage of vector control cell lines (mean ± SD in three separate experiments with duplicates). ND, no colonies
detected.
(B) Tumor growth wasmonitored every 3 days; tumor size and weight were recorded. Data are represented asmean ± SEM from six mice. *p < 0.01 and #p < 0.01
for vector control cells compared with their FBP1-expressing or FBP1-knockdown clones, respectively.
(C) Kaplan-Meier overall survival curve separates the tumors into two groups based on FBP1 expression.
(D) A proposed model to illustrate the transcription repression of FBP1 by Snail in EMT and BLBC, which results in the switch to aerobic glycolysis and increased
b-catenin activity.
See also Figure S8.
Cancer Cell
Metabolic Reprogramming by Snailanalyzer (Seahorse Bioscience, Chicopee, MA). To allow comparison between
experiments, data are presented as OCR in pMol/min/104 cells. Basal OCR
were measured four times and plotted as a function of cells with and without
treatment under the basal condition followed by the sequential addition of oli-
gomycin (1 mg/ml) and FCCP (1 mM) as indicated. The progress curve is anno-
tated to show the relative contribution of basal, ATP-linked and maximal
oxygen consumption after the addition of FCCP, and the reserve capacity of
the cells. The intracellular concentration of F-1,6-BP was examined by treating
cells with 1.25 ml of perchloric acid; cells were then pelleted by centrifugation
at 25003 g for 10 min. The cell pellet was resuspended in 0.2 ml of perchloric
acid (6%) and 0.2 ml of water. After centrifugation, the pH of the combined
supernatant was adjusted to 3.5 with 1% potassium carbonate. F-1,6-BP in
the supernatant was determined spectrophotometrically by measuring the
decrease of NADH to NAD+ at 340 nm. Complex I specific activity was assayed
as described by Sinthupibulyakit (Sinthupibulyakit et al., 2010) by following the
decrease in absorbance due to the oxidation of NADH at 340 nm. The activity
was calculated by the differences with and without the complex I inhibitor,
rotenone.For the [U-13C6]-glucose tracer experiment, Vector- and FBP1-expressing
MDA-MB231 cells were cultured in the DMEM medium with glucose replaced
by 0.1% 13C6-glucose for 24 hr. Polar metabolites were extracted from cells
and media using the acetonitrile/water/chloroform partitioning and 10%
trichloracetic acid methods, respectively. The extracts were subjected to 1D
1H and 1H{13C} HSQC NMR and GC-MS analysis, as previously described
(Fan et al., 2011; Le et al., 2012).DNA Methylation Analysis, ChIP, Quantitative Real-Time PCR,
and Luciferase Reporter Assay
The methods used are described in the Supplemental Experimental
Procedures.Metabolic Assays, Colony Formation Assay, Mammosphere Assay,
and Flow Cytometry Analysis
All methods are described in detail in the Supplemental Experimental
Procedures.Cancer Cell 23, 316–331, March 18, 2013 ª2013 Elsevier Inc. 329
Cancer Cell
Metabolic Reprogramming by SnailXenograft Studies
Female ICR-SCID mice (6–8 weeks old) were purchased from Taconic
(Germantown, NY) and maintained and treated under specific pathogen-free
conditions. All procedures were approved by the Institutional Animal Care
and Use Committee at the University of Kentucky College of Medicine and
conformed to the legal mandates and federal guidelines for the care and
maintenance of laboratory animals. The mice were injected with 1 3 106
FBP1-expressing or knockdown cells on the right MFP and control cells on
the left MFP. The mice were then randomly divided into two groups: standard
water supply and water supplemented with 40mMNAC. Tumor formation was
examined every 2 to 3 days for the whole duration of the experiment. Tumors
were harvested and weighed at the experimental endpoint, and the tumor
mass derived from cells with FBP1 expression or knockdown and vector
control in both flanks of each mouse were compared.
Statistical Analysis
Experiments were repeated at least twice. Results are expressed as mean ±
SD or SEM as indicated. An independent Student’s t test was performed to
analyze the assay results; a two-tailed Student’s t test was used to compare
the intergroup differences. A p value < 0.05 was considered statistically
significant.
ACCESSION NUMBERS
Microarray data of FBP1 expression in MDA-MB231 and Hs578T cells were
deposited at the Gene Expression Omnibus with the accession number
GSE41158.
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Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
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